The estimated Net Worth of Madhavan Balachandran is at least 6.49 百万$ dollars as of 13 June 2024. Mr. Balachandran owns over 2,231 units of Catalent stock worth over 1,416,749$ and over the last 12 years he sold CTLT stock worth over 4,802,942$. In addition, he makes 274,975$ as Independent Director at Catalent.
Sign up
Mr. Balachandran CTLT stock SEC Form 4 insiders trading
Madhavan has made over 11 trades of the Catalent stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 2,231 units of CTLT stock worth 11,423$ on 13 June 2024.
The largest trade he's ever made was selling 30,000 units of Catalent stock on 3 May 2016 worth over 4,623,600$. On average, Madhavan trades about 1,745 units every 84 days since 2013. As of 13 June 2024 he still owns at least 23,759 units of Catalent stock.
You can see the complete history of Mr. Balachandran stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Madhavan Balachandran biography
Madhavan Balachandran is Independent Director of the Company. Mr. Balachandran is Chief Executive Officer of ADRx, Inc., a preclinical stage biotechnology company, a position he has held since August 2019. Previously, he was Executive Vice President, Operations of Amgen Inc., a global biotechnology company, from August 2012 until July 2016 and retired as an Executive Vice President in January 2017. Mr. Balachandran joined Amgen in 1997 as Associate Director, Engineering. He became Director, Engineering in 1998, and, from 1999 to 2001, he held the position of Senior Director, Engineering and Operations Services before moving to the position of Vice President, Information Systems from 2001 to 2002. Thereafter, Mr. Balachandran was Vice President, Puerto Rico Operations from May 2002 to February 2007. From February 2007 to October 2007, Mr. Balachandran was Vice President, Site Operations, and, from October 2007 to August 2012, he held the position of Senior Vice President, Manufacturing. Prior to his tenure at Amgen, Mr. Balachandran held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd., and Burroughs Welcome Company, a predecessor through mergers of GlaxoSmithKline plc. He has served as a director of Stevanato Group since September 2018 and as a director of uniQure NV since September 2017. Mr. Balachandran holds a Master of Science degree in Chemical Engineering from The State University of New York at Buffalo and an MBA from East Carolina University.
What is the salary of Madhavan Balachandran?
As the Independent Director of Catalent, the total compensation of Madhavan Balachandran at Catalent is 274,975$. There are 18 executives at Catalent getting paid more, with John Chiminski having the highest compensation of 8,514,990$.
How old is Madhavan Balachandran?
Madhavan Balachandran is 69, he's been the Independent Director of Catalent since 2017. There are 2 older and 25 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
What's Madhavan Balachandran's mailing address?
Madhavan's mailing address filed with the SEC is C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, SUITE 303, WOBURN, MA, 01801.
Insiders trading at Catalent
Over the last 10 years, insiders at Catalent have traded over 2,686,980,380$ worth of Catalent stock and bought 123,000 units worth 5,376,345$ . The most active insiders traders include Management Associates V L.L...、Peter Zippelius、Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of 22,866,018$. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth 39,429$.
What does Catalent do?
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
What does Catalent's logo look like?
Complete history of Mr. Balachandran stock trades at AMGEN、uniQure N.V、Catalent、Replimune Inc
Catalent executives and stock owners
Catalent executives and other stock owners filed with the SEC include:
-
John Chiminski,
Chairman of the Board, Chief Executive Officer -
Peter Buzy,
Chairman - Gene Therapy -
Alessandro Maselli,
Pres & COO -
John R. Chiminski,
Chairman & CEO -
Alessandro Maselli,
President, Chief Operating Officer -
Jonathan Arnold,
President - Oral Drug Delivery Solutions -
Wetteny Joseph,
Chief Financial Officer, Senior Vice President -
Steven Fasman,
Senior Vice President, General Counsel and Corporate Secretary -
Steven L. Fasman,
Sr. VP, Gen. Counsel & Corp. Sec. -
Karen A. Flynn,
Chief Commercial Officer -
Thomas P. Castellano,
Sr. VP & CFO -
Jack Stahl,
Lead Independent Director -
John Greisch,
Independent Director -
Donald Morel,
Independent Director -
Gregory Lucier,
Independent Director -
Rosemary Crane,
Independent Director -
Rolf Classon,
Independent Director -
J. Martin Carroll,
Independent Director -
Christa Kreuzburg,
Independent Director -
Madhavan Balachandran,
Independent Director -
Peter Zippelius,
Independent Director -
Z Mahdavi,
Vice President of Open Innovation, Biologics, Cell and Gene Therapy -
Jim Walter,
Vice President of Operations for its Oral and Specialty Delivery business -
Scott Gunther,
Senior Vice President - Quality & Regulatory Affairs -
Mike Grippo,
Senior Vice President - Strategy and Corporate Development -
Charles Lickfold,
Senior Vice President, Chief Information Officer -
Ricardo Pravda,
Chief Human Resource Officer, Senior Vice President -
Ricci Whitlow,
President - Clinical Supply Services -
Aristippos Gennadios,
President - Softgel Technologies -
Mario Gargiulo,
Region President, Biologics – Europe -
Karen Flynn,
President - Biologics and Chief Commercial Officer -
Manja Boerman,
President - Cell & Gene Therapy -
Ricardo Pravda,
Sr. VP & Chief HR Officer -
Michael J. Grippo,
Sr. VP of Strategy & Corp. Devel. -
Paul Surdez,
VP of Investor Relations -
Julien Meissonnier,
VP & Chief Scientific Officer -
Ricky Hopson,
VP & Chief Accounting Officer -
Sharon Johnson,
See Remarks -
Uwe Roehrhoff,
Director -
James Quella,
Director -
Management Associates V L.L...,
-
Melvin D Booth,
Director -
Matthew M Walsh,
See Remarks -
Christine Dolan,
See Remarks -
Stephen Leonard,
See Remarks -
Michael J Grippo,
SVP, Strategy & Corp. Dev. -
William Downie,
See Remarks -
Lance Miyamoto,
See Remarks -
Barry Littlejohns,
President, Biologics & SDD -
Paul W Jr Hegwood,
President, CSS -
Scott Houlton,
See Remarks -
Healthcare Partners L.L.C. ...,
10% owner -
Nielsen Kurt,
See Remarks -
Michael J Barber,
Director -
Michael Hatzfeld,
Chief Accounting Officer -
Thomas P Castellano,
SVP, Chief Financial Officer -
Frank A Damelio,
Director -
Michelle R Ryan,
Director -
Stephanie Okey,
Director -
Thomas W Hawkeswood,
Pres. Pharma Prod Delivery Div -
Karen Murphy Santiago,
VP & Chief Accounting Officer -
Patricia Hunt,
Pres. Consumer Health Div -
Michael A. Riley,
Pres. Bio Product Delivery Div -
Lorenzo Carletti,
SVP Global Ops Ph & Cons Hlth -
Kay A Schmidt,
SVP, Enterprise Functions -
Lisa Evoli,
SVP, Chief HR Officer -
Matti Masanovich,
SVP, Chief Financial Officer -
Ricardo Zayas,
SVP, Operations, Biologics NA -
Joseph Anthony Ferraro,
SVP, General Counsel, CCO -
Steven Barg,
Director -
David Mc Erlane,
Group President, Biologics -
Ricky Hopson,
Pres. BioProduct Delivery, CoS